The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma

Virchows Archiv

Volumn 438, Issue 1, 2001, Pages 13-22

  Mentzel, T ^a   Brown, L F ^b   Dvorak, H F ^b   Kuhnen, C ^c   Stiller, K J ^d   Katenkamp, D ^d   Fletcher, C D M ^e  

^a Dermatopathologische Gemeinschaftspraxis   (Germany)

^b Beth Israel Deaconess Medical Centre   (United States)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Liposarcoma; Myxofibrosarcoma; Sarcoma; Soft tissue tumour; Thrombospondin; VEGF

Indexed keywords

CD31 ANTIGEN; COLLAGEN TYPE 1; FLT1 LIGAND; GROWTH FACTOR; MESSENGER RNA; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CELL ULTRASTRUCTURE; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; FIBROSARCOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MYXOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD31; COLLAGEN; DISEASE PROGRESSION; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROSARCOMA; HUMANS; IN SITU HYBRIDIZATION; LIPOSARCOMA, MYXOID; LYMPHOKINES; MALE; MICROCIRCULATION; MIDDLE AGED; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, MESSENGER; THROMBOSPONDIN 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035141265     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004280000327     Document Type: Article

References (59)

1. Microvasculature and VEGF expression in cartilaginous tumors
2. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma
3. Novel methods for the determination of the angiogenic activity in human tumors
4. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors
5. Quantitative microvessel density. A staging and prognostic marker for human prostatic carcinoma
6. Tumor angiogenesis: A quantitative method for histological grading
7. Vascular permeability factor mRNA and protein expression in human kidney
8. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract
9. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas
10. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer
11. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast
12. Uterine leiomyosarcoma has deregulated cell proliferation, but not increased microvessel density compared with uterine leiomyoma
13. Prognostic value of angiogenesis in gastro-intestinal turnouts
14. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2 Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): Correlation with angiogenesis and survival
15. CD31: An immunospecific marker for endothelial differentiation in human neoplasms
16. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels
17. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
18. Angiogenesis and metastasis
19. Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging
20. Quantitative assessment of blood vessel density and size in soft tissue tumors (abstract)
21. Will we ever reliably predict prognosis in a patient with myxoid and round cell liposarcoma?
22. Tumor angiogenesis: Therapeutic implications
23. Induction of angiogenesis during the transition from hyperplasia to neoplasia
24. Microvessel count: An indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma
25. Tumour angiogenesis and prognosis
26. The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumor endothelium
27. Tumour angiogenesis
28. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin
29. Assessment of angiogenesis in breast carcinoma: An important factor in prognosis?
30. Microvessel density and distribution in ductal carcinoma in situ of the breast
31. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
32. Evaluation of microvessel density by computerised image analysis in human renal cell carcinoma. Correlation to pT category, nuclear grade, proliferative activi ty, and occurrence of metastasis
33. Angiogenesis does not correlate with prognosis or expression of vascular endothelial growth factor in synovial sarcoma
34. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma
35. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
36. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the lowgrade variant
37. Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastic-histiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariant analysis
38. Endothelial cell markers CD31, CD34 and BNH9 antibody to H- and Y-antigens - Evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor
39. Proliferative activity, angiogenesis, and necrosis in peripheral nerve sheath tumors: A quantitative evaluation for prognosis
40. Tumor angiogenesis as a prognostic factor in infiltrating lobular carcinoma of the breast
41. Angiogenesis in malignant fibrous histiocytoma
42. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
43. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
44. Vascular endothelial growth factor (VEGF) expression is a prognostic factor in renal cell carcinoma
45. Neovascularity and clinical outcome in high-grade extremity soft tissue sarcomas
46. Vascular surface area as a prognostic indicator for invasive breast carcinoma
47. The prognostic significance of tumor vascularity in in-termediate thickness (0.76-4.0 mm thick) skin melanoma
48. Extent of minor vascularization correlates with prognosis and hematogeneous metastasis in gastric carcinomas
49. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer
50. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours
51. Tumor anglogenesis in breast cancer: Its importance as prognostic indicator and the association with vascular endothelial growth factor expression
52. Different patterns of angiogenesis in sarcomas and carcinomas
53. Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation
54. Tumor angiogenesis: Review of current applications in tumor prognostication
55. Tumoural vascularity as a prognostic factor in cancer patients: The evidence continues to grow
56. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma
57. Tumor angiogenesis: A new significant and independent prognostic indicator in earlystage breast carcinoma
58. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma